{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:41:51Z","timestamp":1785840111514,"version":"3.56.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81541001"],"award-info":[{"award-number":["81541001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bbrc.2019.04.053","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T01:05:40Z","timestamp":1555376740000},"page":"862-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation"],"prefix":"10.1016","volume":"513","author":[{"given":"Zhihua","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinquan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2019.04.053_bib1","first-page":"114","article-title":"The prevalence and prevention of nasopharyngeal carcinoma in China","volume":"30","author":"Cao","year":"2011","journal-title":"Chin. J. Canc."},{"key":"10.1016\/j.bbrc.2019.04.053_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2019.04.053_bib3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.hoc.2015.07.004","article-title":"Chemotherapy for nasopharyngeal carcinoma - current recommendation and controversies","volume":"29","author":"Sze","year":"2015","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.bbrc.2019.04.053_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3892\/ijmm.2013.1538","article-title":"Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells","volume":"33","author":"Zhang","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbrc.2019.04.053_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cam4.982","article-title":"BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma","volume":"6","author":"Gao","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2019.04.053_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bbrc.2019.04.053_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1146\/annurev.biochem.68.1.913","article-title":"eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation","volume":"68","author":"Gingras","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2019.04.053_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0959-440X(03)00009-5","article-title":"Eukaryotic translation initiation factors and regulators","volume":"13","author":"Sonenberg","year":"2003","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrc.2019.04.053_bib9","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","article-title":"Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors","volume":"67","author":"Larsson","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2019.04.053_bib10","series-title":"Inhibition of MNK Pathways Enhances Cancer Cell Response to Chemotherapy with Temozolomide and Targeted Radionuclide Therapy","author":"Grzmil","year":"2016"},{"key":"10.1016\/j.bbrc.2019.04.053_bib11","first-page":"1203","article-title":"Targeting the eIF4E\/beta-catenin axis sensitizes cervical carcinoma squamous cells to chemotherapy","volume":"9","author":"Xu","year":"2017","journal-title":"Am. J. Tourism Res."},{"key":"10.1016\/j.bbrc.2019.04.053_bib12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/345544a0","article-title":"Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap","volume":"345","author":"Lazaris-Karatzas","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2019.04.053_bib13","first-page":"1343","article-title":"Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis","volume":"20","author":"Zimmer","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2019.04.053_bib14","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2019.04.053_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.18632\/oncotarget.453","article-title":"Targeting Mnks for cancer therapy","volume":"3","author":"Hou","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2019.04.053_bib16","article-title":"Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma","volume":"9","author":"Zheng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2019.04.053_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12032-012-0400-z","article-title":"EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma","volume":"30","author":"Wu","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bbrc.2019.04.053_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4254\/wjh.v8.i2.123","article-title":"Ribavirin: past, present and future","volume":"8","author":"Loustaud-Ratti","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.bbrc.2019.04.053_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","article-title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","volume":"114","author":"Assouline","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2019.04.053_bib20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/0008-5472.CAN-14-1996","article-title":"Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis","volume":"75","author":"Pettersson","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2019.04.053_bib21","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1182\/blood-2003-07-2193","article-title":"Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells","volume":"103","author":"Kharas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2019.04.053_bib22","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.18632\/oncotarget.13772","article-title":"Inhibiting the MNK-eIF4E-beta-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.bbrc.2019.04.053_bib23","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41388-018-0567-7","article-title":"Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia","volume":"38","author":"Urtishak","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2019.04.053_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.bbrc.2016.12.025","article-title":"Inhibition of mTOR\/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma","volume":"482","author":"Dai","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2019.04.053_bib25","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/leu.2011.57","article-title":"Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens","volume":"25","author":"Kraljacic","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2019.04.053_bib26","doi-asserted-by":"crossref","first-page":"18105","DOI":"10.1073\/pnas.0406927102","article-title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","volume":"101","author":"Kentsis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2019.04.053_bib27","doi-asserted-by":"crossref","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","article-title":"Identification of a novel inhibitor of mitogen-activated protein kinase kinase","volume":"273","author":"Favata","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2019.04.053_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cncr.20768","article-title":"Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma","volume":"103","author":"Ma","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2019.04.053_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123352","article-title":"Phosphorylation of eIF4E confers resistance to cellular stress and DNA-damaging agents through an interaction with 4E-T: a rationale for novel therapeutic approaches","volume":"10","author":"Martinez","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2019.04.053_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Boussemart","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2019.04.053_bib31","series-title":"Identification of the Best Direct-Acting Antiviral Regimen for Patients with Hepatitis C Virus Genotype 3 Infection: a Systematic Review and Network Meta-Analysis, Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the","author":"Berden","year":"2016"},{"key":"10.1016\/j.bbrc.2019.04.053_bib32","article-title":"Ribavirin inhibits the activity of mTOR\/eIF4E, ERK\/Mnk1\/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemia","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbrc.2019.04.053_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12094-017-1786-z","article-title":"Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma","volume":"20","author":"Cao","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbrc.2019.04.053_bib34","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1261\/rna.2238705","article-title":"Further evidence that ribavirin interacts with eIF4E","volume":"11","author":"Kentsis","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.bbrc.2019.04.053_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.163","article-title":"Ribavirin targets eIF4E dependent Akt survival signaling","volume":"375","author":"Tan","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2019.04.053_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.molcel.2015.06.020","article-title":"ERK2 mediates metabolic stress response to regulate cell fate","volume":"59","author":"Shin","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2019.04.053_bib37","first-page":"4639","article-title":"The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome","volume":"29","author":"Ohta","year":"2009","journal-title":"Anticancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19306813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19306813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:37:16Z","timestamp":1757763436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X19306813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0006291X19306813"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.04.053","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.04.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}